APARTSIN, K.A., N. A. SVERDLOVA, V. V. KIREEVA, Abanoub RIAD and Miloslav KLUGAR. International COVID-19 Vaccines Safety Tracking Study (CoVaST-RU): Participation of the Russian Federation. Profilakticheskaya meditsina. 2021, vol. 24, No 12, p. 31-40. ISSN 2305-4948. Available from: https://dx.doi.org/10.17116/profmed20212412131.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name International COVID-19 Vaccines Safety Tracking Study (CoVaST-RU): Participation of the Russian Federation
Authors APARTSIN, K.A., N. A. SVERDLOVA, V. V. KIREEVA, Abanoub RIAD (818 Egypt, belonging to the institution) and Miloslav KLUGAR (203 Czech Republic, belonging to the institution).
Edition Profilakticheskaya meditsina, 2021, 2305-4948.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30304 Public and environmental health
Country of publisher Russian Federation
Confidentiality degree is not subject to a state or trade secret
WWW URL
RIV identification code RIV/00216224:14110/21:00124034
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.17116/profmed20212412131
Keywords in English COVID-19; vaccination; side effects; Gam-COVID-Vac (Sputnik V); CoviVac; Sputnik Light
Tags rivok
Tags International impact
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 17/5/2022 13:04.
Abstract
Side effects associated with COVID-19 vaccines play a crucial role in the public decision regarding the importance and necessity of vaccination. Objective. Global active surveillance of the safety and efficacy of COVID-19 vaccines. The importance of participation of the Russian Federation is determined by obtaining data on the efficacy and safety of vaccines approved for use in the country, such as GamCOVID-Vac (Sputnik V), EpiVacCorona, CoviVac, and Sputnik Light, and comparing them with vaccines used abroad. Material and methods. The international study includes 3 phases to evaluate vaccine efficacy and safety in target populations. The first phase will study adverse reactions associated with primary vaccination, the second phase will investigate the side effects of booster doses, and the third phase will assess the long-term safety and efficacy of COVID-19 vaccines. Validated electronic questionnaires completed by the target population will be used for data collection. Expected results. The study will provide evidence-based data on the efficacy and safety of domestic vaccines in comparison with foreign vaccines. The study protocol is registered at ClinicalTrials.gov under the identifier NCT04834869. Russian Federation (CoVaST-RU) is included in the study on 26 July 2021.
PrintDisplayed: 22/8/2024 09:12